title: A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer.
abstract: OBJECTIVE
  To analyze the results of fertility-sparing treatment of early-stage endometrial cancer (EC) in patients treated at Turkish gynecologic oncology centers, and to present a review of the literature.
  
  
  METHODS
  Thirteen healthcare centers in Turkey were contacted to determine if they were eligible to participate in the study. Centers that were eligible and agreed to participate were sent a database form to record the demographic characteristics, clinicopathologic findings, and follow-up results for their EC patients.
  
  
  RESULTS
  Eleven Turkish healthcare centers provided data on 43 EC patients. Mean duration of treatment was 5 months and mean follow-up was 49 months. In total, 35 (81.4%) patients were tumor free following primary progesterone therapy. Mean time from the end of progesterone therapy to pregnancy was 10.6 ± 4.3 months (range, 3-18 months). Two patients had tumor recurrence during follow-up. The pregnancy rate among the 31 women who actively sought pregnancy was 41.9% (n=13).
  
  
  CONCLUSIONS
  Conservative management of early-stage EC in women of reproductive age using oral progestins was effective and did not compromise oncological outcome. Pregnancy in the study patients was achieved spontaneously and artificially.
authors.affiliation: Department of Obstetrics and Gynecology, Baskent University School of Medicine, Ankara, Turkey. pdursun@yahoo.com
authors.forename: Polat
authors.initials: P
authors.lastname: Dursun
authors.forename: Serkan
authors.initials: S
authors.lastname: Erkanli
authors.forename: Ahmet Bariş
authors.initials: AB
authors.lastname: Güzel
authors.forename: Murat
authors.initials: M
authors.lastname: Gultekin
authors.forename: Nefise Cagla
authors.initials: NC
authors.lastname: Tarhan
authors.forename: Ozden
authors.initials: O
authors.lastname: Altundag
authors.forename: Fuat
authors.initials: F
authors.lastname: Demirkiran
authors.forename: Tugan
authors.initials: T
authors.lastname: Beşe
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yildirim
authors.forename: Gurkan
authors.initials: G
authors.lastname: Bozdag
authors.forename: Hakan
authors.initials: H
authors.lastname: Yarali
authors.forename: Tayyup
authors.initials: T
authors.lastname: Simsek
authors.forename: Bulent
authors.initials: B
authors.lastname: Ozcelik
authors.forename: Firat
authors.initials: F
authors.lastname: Ortaç
authors.forename: Salih
authors.initials: S
authors.lastname: Taskin
authors.forename: Tevfik
authors.initials: T
authors.lastname: Guvenal
authors.forename: Nejat
authors.initials: N
authors.lastname: Ozgul
authors.forename: Ali
authors.initials: A
authors.lastname: Haberal
authors.forename: M Ali
authors.initials: MA
authors.lastname: Vardar
authors.forename: Murat
authors.initials: M
authors.lastname: Dede
authors.forename: Mufit
authors.initials: M
authors.lastname: Yenen
authors.forename: Aytekin
authors.initials: A
authors.lastname: Altintas
authors.forename: Macit
authors.initials: M
authors.lastname: Arvas
authors.forename: Ali
authors.initials: A
authors.lastname: Ayhan
mesh_terms: D000284:Administration, Oral; D000328:Adult; D016889:Endometrial Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D059247:Fertility Preservation / Q000379:methods*; D005500:Follow-Up Studies; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage / Q000627:therapeutic use*; D011372:Progestins / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D014421:Turkey; D055815:Young Adult
chemical_list: D011372:Progestins; D011374:Progesterone